Total raised
$30.5M
Last: Undisclosed 2022-04
Stage
Series A
Founded
2013
Headcount
5
HQ
Yavne
Sector
Health Tech & Life Sciences
About
Metabomed is a drug-discovery company in the field of cancer metabolism, with a proprietary target-identification platform based on computational biology and metabolomics. The company focuses on developing drugs that inhibit targets that form a synthetic lethal gene pair with metabolic genes inactivated in cancer cells. Using this target-inhibiting strategy, Metabomed intends to develop more selective, highly focused anticancer drugs with the ability to kill cancer cells without harming normal cells.
Funding history · 4 rounds · $30.5M total
2022-04
Undisclosed
Undisclosed
2019-12
Undisclosed
$12.5M
2016-04
Series A
$18.0M
2014-05
Series A
Undisclosed
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCellsGenes
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
pharma-companiestargeted-therapyoncologybiotechnologybiopharmaceuticalcancerdrug-discoverygenomics